There is a fundamental problem with the way scientists test new drugs: even as laboratory-grown human tissues become increasingly sophisticated, the environments in which they are studied often remain remarkably primitive.
Norwegian biotech startup Vitroscope thinks it has a solution. Rather than simply placing living human cells in plastic laboratory dishes, its technology attempts to recreate the physical conditions those cells would experience inside the body, keeping tissue alive and functioning for days while scientists observe how it responds to experimental treatments.
Earlier this month, the Trondheim-based company announced $7 million in new funding, comprising a $5 million seed round co-led by Cerberus Ventures and YZR Capital, alongside $2 million in non-dilutive funding from the Research Council of Norway.
The investment brings Vitroscope's total funding to $8.8 million and will support commercialisation of its first product, vitro.alive, while advancing a higher-throughput version, vitro.scale.
But in an exclusive interview with Pathfounders, the company's three co-founders said the sky’s the limit on the trechnology.
The Matrix analogy
According to co-founder and CEO Carlo Kriesi, advances in organoids (miniature, lab-grown structures designed to reproduce aspects of human organs) and other tissue models have outpaced the technology researchers use to study them.
Scientists can now produce increasingly realistic biological models, but conventional laboratory methods struggle to recreate the environment in which those tissues naturally function.
"If you take a liver tissue out of a body, and you put it in a well plate, you no longer have a liver tissue. You have liver cells in a plastic dish," Kriesi explains.
"What we're doing is we're making this liver tissue believe it's still in the human liver, so that it continues functioning and behaving like in a human liver." He jokes that it’s a little like Keanu Reeves’ character in The Matrix, who thinks he’s walking around the world normally when, in fact, he’s inside a plastic bubble, sustained by AI robots.
The company's approach involves controlling several key environmental factors: temperature, oxygen, pH and fluid flow.
Its benchtop device, vitro.alive, circulates nutrient-rich liquid around living tissue samples, helping simulate the conditions they would experience inside the human body. Integrated sensors and microscopy allow researchers to monitor biological changes over extended periods.
The system can run six independent experiments in parallel, and works with existing tissue models and standard inverted microscopes.
Co-founder and CTO Heikki Sjöman explains that the process combines software, biological data and proprietary hardware.
"We use publicly available data to get the conditions" experienced by different tissues, he says, before applying "those conditions through our own hardware."
The technology is designed to make complex experiments accessible to researchers without requiring them to develop their own bespoke laboratory systems.
From cancer biopsies to Alzheimer's research
One of the more compelling applications involves testing new cancer treatments directly on human tissue samples.
Sandra Jernström, Vitroscope's co-founder and Chief Business Development Officer, previously worked in precision cancer medicine, including as a co-founder and Chief Scientific Officer of a Paris-based startup.
Her work involved attempting to identify which drugs would be most effective for individual patients.
But conventional approaches often required breaking tissue samples apart into individual cells, destroying the architecture that helps determine how the tissue behaves.
Vitroscope's approach instead aims to preserve the original tissue structure, allowing researchers to observe how treatments interact with a more intact biological system.
"We're not specifically focusing one disease, but we actually work with experts in order to enable many different tissue types," says Jernström.
That means the technology could potentially be applied to cancer, neurodegenerative diseases and a much wider range of medical research.
"Regardless of whether you're trying to find a new cure for Alzheimer's or if it's a cancer drug, then we can have that model that you need, which is from a human," she says.
The company also sees an opportunity to reduce reliance on animal experimentation.
"Instead of having a mouse model, we can actually have a more humanised model," Jernström says.
Where animal tissue remains necessary, she explains, the technology could potentially allow multiple experiments to be performed using slices from a single animal's tissue, reducing the number of animals required.
Vitroscope has already reported several research demonstrations. Working with Instant Bio, it maintained vascularised human brain organoids under controlled fluid flow for seven days.
In separate experiments, primary human liver cells formed organised tissue structures on the platform that did not develop in conventional well plates. Other research examined how kidney cells responded to physiological fluid flow.
These are early research findings rather than proof of clinical effectiveness, but they illustrate the company's central proposition: keeping tissue in a more realistic environment may yield observations that conventional experiments miss.
Hardware, meets AI, meets consumables
But Vitroscope is not purely a software company. Its commercial model combines laboratory hardware, software and consumables. Experiments require sterile components that are replaced between tests to prevent contamination, particularly when toxic drug compounds are involved.
The company's next challenge is scaling the technology.
Its current vitro.alive platform supports six simultaneous experiments. Its planned successor, vitro.scale, is being developed to handle 96 parallel experiments, making it more suitable for laboratories screening larger numbers of potential drug candidates.
Customer testing is expected to begin in 2027, with commercial launch planned for 2028. But there is another potentially important dimension to the business: data.
As pharmaceutical companies increasingly turn to AI to discover and develop medicines, the quality of the biological information used to train and validate those models becomes critical.
Sjöman believes Vitroscope could help produce more useful data by recording how living human tissue behaves under realistic conditions.
"When you can produce lifelike data, then you can use that to tune any kind of model to get the right answers," he says.
The argument is that better biological experiments could produce more human-relevant datasets for computational drug discovery, rather than relying exclusively on conventional cell studies or animal experiments.
It is a longer-term opportunity, rather than evidence that Vitroscope has already developed an AI system capable of predicting clinical outcomes.
The backstory
Kriesi's interest in the technology dates back to his background in mechanical and biomedical engineering.
He recalls being fascinated by research demonstrating that controlling the physical environment around cells could reproduce biological responses otherwise observed only inside living organisms. So, he thought, why wasn't everyone doing this?
The answer, he discovered, was the difficulty of conducting the experiments. "Turns out the reason is that it's very complex experiments that take a lot of time to run," he says.
That problem became the focus of the work that ultimately led to Vitroscope: engineering a platform that could automate and simplify experiments previously requiring substantial specialist expertise.
The company, incorporated in 2019, developed out of research connections in Norway. Its founders bring together engineering, laboratory automation and precision medicine expertise across the Nordic region.
However, raising capital for such a hardware-intensive life sciences business has not been straightforward.
"It was definitely hard," acknowledges Kriesi. "The life science market has not exactly been blessed over the last couple of years."
Nevertheless, the company's financing arrives as regulators and pharmaceutical companies show growing interest in research methods that use human-relevant biological models.
In September, the US Food and Drug Administration clarified that non-animal methods could support drug and biological-product safety testing where appropriate, part of a broader shift towards alternatives to traditional animal studies.
For Vitroscope, that creates an opportunity to position its technology within a changing drug development industry.
Helping doctors choose treatments
The long-term vision is considerably more ambitious than improving preclinical drug experiments.
Kriesi wants Vitroscope to build a library of validated tissue models, supported by retrospective clinical trial data, that could eventually demonstrate how closely laboratory responses correspond with real patient outcomes.
That could open the door to more personalised treatment decisions, particularly in fields such as oncology, where different patients can respond very differently to the same medication.
The goal is not simply to keep tissues alive for longer, but to establish whether their responses in the laboratory can reliably predict what happens to patients.
For now, that remains an ambition requiring extensive validation.
But Kriesi says the opportunity is to super-charge modern medicine.
"What happens when a patient walks into a hospital?" he asks. "How do you know what treatment to give that patient?"
Vitroscope’s potential is that, by keeping a tiny piece of living human tissue functioning outside the body, you could see what happens when a drug is introduced. In other words, this could lead to highly tailored, personalised medicine.


